MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp(a) inhibitor from China's Jiangsu Hengrui Pharma for $200 million upfront. The deal gives MSD exclusive rights to the ...
Kelun-Biotech has become the second drugmaker to bring a TROP2-directed antibody-drug conjugate to regulatory approval, getting a green light in China for sacituzumab tirumotecan (sac-TMT). The ...
Abstract: Lane-changing is a typical scenario of driver interaction, which causes a multitude of traffic crashes as well. Therefore, clarifying the lane-changing interaction process is of great ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback